Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator

Fig. 2

Study design. TP = treatment period. aThe figure shows an example of the washout timings for one patient. The washout period was 10 to 21 days following navafenterol or placebo, and 7 to 21 days following the active comparators indacaterol and tiotropium. Therefore the length of each washout period depended on the patient’s randomization sequence. One exception per patient of up to 28 days was considered acceptable; bdays following administration of last dose

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us